Progress of Preparation and Applications of 68Ga-Labelled Radiopharmaceuticals

doi:10.7538/tws.2017.youxian.015

Abstract

Abstract:

Positron emission tomography (PET) has become the leading technology in the field of nuclear medicine. Currently, PET is widely used in tumor research, with high sensitivity, good resolution and so on. The construction of the ⁶⁸Ge/ ⁶⁸Ga generator has increased the application of ⁶⁸Ga radiopharmaceuticals. The ⁶⁸Ga radiopharmaceuticals are mainly applied on the imaging of oncological diseases, such as the targeting imaging of somatostatin receptor, human epidermal growth factor receptor, folate and so on. The potential for imaging of pulmonary and myocardial perfusion and ventilation as well as targeting imaging of inflammation, infection, have also been considered and fundamental exploration is ongoing. The application progress of ⁶⁸Ga radiopharmaceuticals was reviewed, including production, receptors and derivatives, imaging of pre-clinical developments on diagnosis.

Key words: ⁶⁸Ga, labeled, radiopharmaceuticals, PET imaging

摘要：

正电子发射计算机断层显像(positron emission tomography, PET)为核医学领域的显像方法之一，广泛应用于肿瘤研究，灵敏度高，分辨率佳。近年来，⁶⁸Ge/⁶⁸Ga发生器的开发促进了⁶⁸Ga标记的PET显像药物的研究和应用。⁶⁸Ga放射性药物主要应用于肿瘤显像，如生长抑素受体、人表皮生长因子受体、叶酸等受体分子的靶向显像；也可用于心肌灌注、肺灌注和通气、炎症和感染显像等。本文主要介绍⁶⁸Ga标记放射性药物相关的生产，标记涉及的受体及衍生物，以及显像研究等应用进展。

关键词: ⁶⁸Ga, 标记, 放射性药物, PET显像

YANG Chun-hui;LIANG Ji-xin;SHEN Lang-tao;LI Hong-yu. Progress of Preparation and Applications of ⁶⁸Ga-Labelled Radiopharmaceuticals[J]. Journal of Isotopes, 2017, 30(3): 209-218.

杨春慧;梁积新;沈浪涛;李洪玉. ⁶⁸Ga标记放射性药物的制备及应用研究进展[J]. 同位素, 2017, 30(3): 209-218.

References

［1］Ronald E W, Mathew L T. Chemistry of gallium and indium radiopharmaceuticals［M］. England: Handbook of Radiopharmaceuticals, 2003.
［2］Irina V. Prospective of ⁶⁸Ga-radiopharmaceutical development［J］. Theranostics, 2014, 4(1): 47-80.
［3］Helmut R, Michael H, Haberkorn U. ⁶⁸Ga-Labeled peptides in tumor imaging［J］. Journal of Nuclear Medicine, 2005, 46(suppl 1): 172-178.
［4］Zhernosekov K P, Filosofov D V. Processing of generator-［roduced ⁶⁸Ga for edical application［J］. Journal of Nuclear Medicine, 2007, 48(10): 1741-1748.
［5］傅红宇，罗文博，沈亦佳，等. ⁶⁸Ge/⁶⁸Ga发生器吸附剂SnO₂的制备［J］. 核化学与放射化学，2011，33（4）：240-44.Fu Hongyu, Luo Wenbo, Shen Yijia, et al. Preparation of SnO₂ used as absorbent of ⁶⁸Ge-⁶⁸Ga generator［J］.Journal of Nuclear and Radiochemistry, 2011, 33（4）: 240-244(in Chinese).
［6］Kumar V, Boddeti D K, Evans S G, et al. Potential use of Ga-68-apo-transferrin as a PET imaging agent for detecting staphylococcus aureus infection［J］. Nuclear Medicine and Biology, 2011, 38(3): 393-398.
［7］Raquel G, Lurdes G B, Sebestík J, et al. New tripodal hydroxypyridinone based chelating agents for Fe(Ⅲ), Al(Ⅲ) and Ga(Ⅲ): Synthesis, physico-chemical properties and bioevaluation［J］. Journal of Inorganic Biochemistry, 2009, 103(2): 262-273.
［8］杨春慧，沈浪涛，邓新荣，等. 3-羟基-4-吡啶酮衍生物的合成［J］. 中国原子能科学研究院年报，2008，00：297-297.Yang Chunhui, Shen Langtao, Deng Xinrong, et al. Synthesis of 3-hydroxy-4-pyridinone derivative［J］. Annual Report of China Institute of Atomic Energy, 2008, 00: 297-297(in Chinese).
［9］Al-Nahhas A, Fanti S. Radiolabelled peptides in diagnosis and therapy: an introduction［J］. Eur J Nucl Med Mol Imaging, 2012, 39(Suppl 1): S1-S3.
［10］Ambrosini V, Campana D, Tomassetti P, et al. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET［J］. Eur J Nucl Med Mol Imaging, 2012, 39（Suppl 1): S52-S60.
［11］Oberg K E, Reubi J C, Kwekkeboom D J, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy［J］. Gastroenterology, 2010, 139: 742-753.
［12］Tan E H, Goh S W. Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT［J］. World J Radiol, 2010, 2: 55-67.
［13］Naji M, AL-Nahhas A. ⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours［J］. Eur J Nucl Med Mol Imaging, 2012, 39(Suppl1): S61-S67.
［14］Reubi J C, Schär J C, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use［J］. Eur J Nucl Med Mol Imaging, 2000, 27(3): 273-282.
［15］Poeppel T D, Binse I, Petersenn S, et al. ⁶⁸Ga-DOTATOC versus ⁶⁸Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors［J］. J Nucl Med, 2011, 52(12): 1864-1870.
［16］Kabasakal L, Demirci E, Ocak M, et al. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours［J］. Eur J Nucl Med Mol Imaging, 2012, 39(8): 1271-1277.
［17］Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, et al. Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography［J］. J Nucl Med Mol Imaging, 2010, 54(1): 52-60.
［18］Gilardi L, Vadrucci M, Grana C M. Multiple vertebral hemangiomas: a potential pitfall in ⁶⁸Ga-DOTATOC PET/CT interpretation［J］. Endocrine, 2017, 55(3): 992-993.
［19］Cingarlini S, Ortolani S, Salgarello M, et al. Role of combined ⁶⁸Ga-DOTATOC and ¹⁸F-FDG positron emission tomography/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: implications for managing surgical decisions［J］. Pancreas, 2017, 46(1): 42-47.
［20］Ronald W, Stephen D, Gary S, et al. ⁶⁸Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer［J］. PLoS One, 2017, 12(2): e0171301.
［21］于江媛, 李洁, 李囡, 等. 胃肠胰神经内分泌肿瘤患者⁹⁹Tc^m-HYNIC-TOC SPECT与⁶⁸Ga-DOTA-TATE PET/CT显像的对比研究［J］. 中华核医学与分子影像学杂志,2015,35(4):289-292.Yu Jiangyuan, Li Jie, Li Nan, et al. An intrapatient comparison of ^99mTc-HYNIC-TOC imaging and ⁶⁸Ga-DOTA-TATE imaging on patients with gastroenteropancreatic neuroendocrine neoplasms［J］. Chin J Nucl Med Mol Imaging, 2015, 35(4): 289-292(in Chinese).
［22］Tarkin J M, Joshi F R, Evans N R, et al. Detection of atherosclerotic inflammation by ⁶⁸Ga-DOTATATE PET compared to ［¹⁸F］FDG PET imaging［J］. J Am Coll Cardiol, 2017, 69(14): 1774-1791.
［23］Li X, Bauer W, Kreissl M C, et al. Specific somatostatin receptor II expression in arterial plaque: ⁶⁸Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice［J］. Atherosclerosis, 2013, 230(1): 33-39.
［24］Buck A K, Herrmann K, Schreyogg J. PET/CT for staging lung cancer: costly or cost-saving［J］ Eur J Nucl Med Mol Imaging, 2011, 38: 799-801.
［25］Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, et al. Pharmacokinetic studies of ⁶⁸Ga-labeled bombesin (⁶⁸Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: Preliminary results［J］. Clin Nucl Med, 2011, 36(2): 101-108.
［26］Schroeder R P, van Weerden W M, Krenning E P, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38(7): 1257-1266.
［27］Liu Z, Niu G, Wang F, et al. ⁶⁸Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imagin［J］. Eur J Nucl Med Mol Imaging, 2009, 36(9): 1483-1494.
［28］Brom M, Oyen W J, Joosten L, et al. ⁶⁸Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET［J］. Eur J Nucl Med Mol Imaging, 2010, 37(7): 1345-1355.
［29］Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT［J］. J Nucl Med, 2010, 51(7): 1059-1067.
［30］Hennrich U, Seyler L, Schafer M, et al. Synthesis and in vitro evaluation of ⁶⁸Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression［J］. Bioorg Med Chem, 2012, 20(4): 1502-1510.
［31］Sandstrom K, Haylock A K, Velikyan I, et al. Improved tumor-to-organ ratios of a novel ⁶⁷Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules［J］. Cancer Biother Radio, 2011, 26(5): 593-601.
［32］Baum R P, Prasad V. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic ¹¹¹In or ⁶⁸Ga-labeled affibody molecules［J］. J Nucl Med, 2010, 51: 892-897.
［33］王龙，唐军，刘增礼,等. ⁶⁸Ga-DOTA-cRGD的制备及对荷肺腺癌裸鼠的显像研究［J］. 中华核医学与分子影像杂志，2016，36(02):127-130.Wang Long, Tang Jun, Liu Zengli, et al. Preparation of ⁶⁸Ga-DOTA-cRGD and its utility for lung adenocarcinoma bearing nude mice imaging［J］. Chin J Nucl Med Mol Imaging, 2016，36(02): 127-130(in Chinese).
［34］Peter A K, Chuangyan Z, Christine R. ［⁶⁸Ga］-FSC-(RGD)₃ a trimeric RGD peptide for imaging αvβ₃ integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation［J］. Nuclear Medicine and Biology, 2015, 42 (2): 115-122.
［35］Blom E, Velikyan I, Monazzam A, et al. Synthesis and characterization of scVEGF-PEG-［⁶⁸Ga］NOTA and scVEGF-PEG-［⁶⁸Ga］DOTA PET tracers［J］. J Labelled Comp Radiopharm, 2011, 54(7): 685-692.
［36］Azhdarinia A, Wilganowski N, Robinson H, et al. Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide［J］. Bioorg Med Chem, 2011, 19(12): 3769-3776.
［37］Fellner M, Baum R P, Kubicek V, et al. PET/CT imaging of osteoblastic bone metastases with Ga-68-bisphosphonates: first human study［J］. Eur J Nucl Med Mol Imaging, 2010, 37(4): 834.
［38］Fernandez S, Dematteis S, Giglio J, et al. Synthesis, in vitro and in vivo characterization of two novel ⁶⁸Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia［J］. Nucl Med Biol, 2012, 40(2): 273-279.
［39］Yang Z, Xiong C, Zhang R, et al. Synthesis and evaluation of ⁶⁸Ga-labeled DOTA-2-deoxy-D-glucosamine as a potential radiotracer in muPET imaging［J］. Am J Nucl Med Mol Imaging, 2012, 2(4): 499-507.
［40］Maus S, Buchholz H G, Ament S, et al. Labelling of commercially available human serum albumin kits with ⁶⁸Ga as surrogates for ^99mTc-MAA microspheres［J］. Appl Radiat Isot, 2011, 69(1): 171-175.
［41］Choi J Y, Jeong J M, Yoo B C, et al. Development of Ga-68-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography［J］. Nucl Med Biol, 2011, 38(3): 371-379.
［42］Ndiege N, Raidoo R, Schultz M K, et al. Preparation of a versatile bifunctional zeolite for targeted imaging applications. langmuir［J］. the ACS journal of surfaces and colloids. 2011, 27(6): 2904-2909.
［43］Fani M, Tamma M L, Nicolas G P, et al. In vivo imaging of folate receptor positive tumor xenografts using novel ⁶⁸Ga-NODAGA-folate conjugates［J］. Molecular pharmaceutics, 2012, 9(5): 1136-1145.
［44］Persson M, Madsen J, Ostergaard S, et al. ⁶⁸Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers［J］. Nucl Med Biol, 2012, 39: 560-569.
［45］Fellner M, Dillenburg W, Buchholz H G, et al. Assessing p-glycoprotein (Pgp) activity in vivo utilizing ⁶⁸Ga-Schiff base complexes［J］. Mol Imaging Biol, 2011, 13(5): 985-994.
［46］Afshar-Oromieh A, Haberkorn U, Eder M, et al. ［⁶⁸Ga］Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with ¹⁸F-FECH［J］. Eur J Nucl Med Mol Imaging, 2012, 39(6): 1085-1086.
［47］Lütje S I, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using ⁶⁸Ga HBED-CC-PSMA PET/CT［J］. Clin Nucl Med, 2017, 42(1): 20-25.
［48］崔璨，邵国强，徐志红. ⁶⁸Ga PSMA-11标记合成及生物分布和代谢动力学研究［J］. 中华核医学与分子影像杂志，2016，36(02):106-111.Cui Can, Shao Guoqiang, Xu Zhihong.Synthesis of ⁶⁸Ga PSMA-11 and evaluation of its biodistribution and kinetics in mice［J］. Chin J Nucl Med Mol Imaging, 2016，36(02): 106-111(in Chinese).
［49］Sasikumar A, Joy A, Pillai M R, et al. Diagnostic value of ⁶⁸Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis［J］. Clin Nucl Med, 2017, 42(1): e41-e48.
［50］Richter T, Bergmann R, Pietzsch J, et al. Effects of posture on regional pulmonary blood flow in rats as measured by PET［J］. Journal of Applied Physiology, 2010, 108(2): 422-429.
［51］Borges J B, Velikyan I, Långström B, et al. Ventilation distribution studies comparing technegas and gallgas using ⁶⁸GaCl₃ as the label［J］. The Journal of Nuclear Medicine, 2011, 52(2): 206-209.
［52］黄斌,方纬,田伟. ⁶⁸Ga-NOTA-Duramycin实验研究的标记与生物分布［J］. 中华核医学与分子影像学杂志,2012,32(4):286-290.Huang Bin, Fang Wei, Tian Wei, et al. Experimental study of labeling and biodistribution of ⁶⁸Ga-NOTA-Duramycin［J］. Chin J Nucl Med Mol Imaging, 2012, 32(4): 286-290(in Chinese).
［53］Petrik M, Haas H, Schrettl M, et al. In vitro and in vivo evaluation of selected ⁶⁸Ga-siderophores for infection imaging［J］. Nucl Med Biol, 2012, 39(3): 361-369.
［54］Petrik M, Franssen G M, Haas H, et al. Preclinical evaluation of two ⁶⁸Ga-siderophores as potential adiopharmaceuticals for Aspergillus fumigatus infection imaging［J］. Eur J Nucl Med Mol Imaging, 2012, 39: 1175-1183.
［55］Nanni C, Errani C, Boriani L, et al. ⁶⁸Ga-Citrate PET/CT for evaluating patients with infections of the bone: preliminary results［J］. J Nucl Med, 2010, 51(12): 1932-1936.
［56］王玲,蔡炯,朱朝晖. ⁶⁸Ga-枸橼酸制备及炎症显像［J］. 医学研究杂志,2014,43(12):67-70.Wang Ling, Cai Jiong, Zhu Zhaohui. ⁶⁸Ga-Citrate preparation and inflammation imaging［J］. J Med Res, 2014, 43(12): 67-70（in Chinese）.
［57］Demirkol M O, Kiremit M C, Acar O, et al. The utility of ⁶⁸Ga-PSMA PET/CT in poorly differentiated metastatic prostate cancer［J］. Clin Nucl Med, 2017, 42(5): 403-405.
［58］Noto B, Büther F, Springe K A D, et al. Impact of PET acquisition durations on image quality and lesion detectability in whole-body ⁶⁸Ga-PSMA PETMRI［J］. Ejnmmi Res, 2017, 7(1): 1-12.
［59］Aydin F, Akçal A, Ünal B, et al. ⁶⁸Ga-PSMA uptake by dermatofibroma in a patient with prostate cancer［J］. Clin Nucl Med, 2017, 42(5): 358-360.

[1]	HUANG Wei, CHEN Baojun, ZHAO Siqian. Development status of ³H and ¹⁴C Radiolabeled Compounds [J]. Journal of Isotopes, 2021, 34(2): 175-180.
[2]	ZHAO Hailong;LI Hongyu. Research Progress of ⁶⁴Cu-Radiopharmaceuticals in Clinical Trial for Tumor Diagnosis [J]. Journal of Isotopes, 2021, 34(1): 78-88.
[3]	HUANG Xuhu;LI Hongyu. Development of Radiolabeled Duramycin for Apoptosis Imaging [J]. Journal of Isotopes, 2020, 33(6): 435-442.
[4]	SUN Wen;LI Jie;DU Xiaoning;XU Zhongjie;PAN Jie;YOU Yafang;LI Meihua. Study on the Application of Phthalate Esters in The Detection of Plasticizer in Infant Milk Powder [J]. Journal of Isotopes, 2020, 33(5): 279-285.
[5]	GUO Zhide;ZHANG Xianzhong;DU Jin. The Research Progress of ⁶⁸Ga Generator and ⁶⁸Ga Radiopharmaceuticals [J]. Journal of Isotopes, 2019, 32(5): 360-374.
[6]	ZHANG Jinming;DU Jin. Preparation of Radiopharmaceuticals in China: Current Status and Prospects [J]. Journal of Isotopes, 2019, 32(3): 178-185.
[7]	XU Jianfei;LIU Zhanfeng;LU Weijing;LEI Wen;HOU Jie;DU Xiaoning. Synthesis of Isotope Labeled Protocatechuic Acid-(¹³COOH) [J]. Journal of Isotopes, 2018, 31(4): 216-221.
[8]	TIAN Jiale;JIA Hongmei. Current Status and Prospects of ^99mTc-radiopharmaceuticals [J]. Journal of Isotopes, 2018, 31(3): 143-156.
[9]	YOU Lin-yi;GUO Zhi-de;ZHANG Xian-zhong. Current Status and Prospects of Radiopharmaceuticals for Diagnosis [J]. Journal of Isotopes, 2017, 30(4): 292-306.
[10]	HUANG Qian-huan;PAN Dong-hui;XU Yu-ping;SHENG Jie;WANG Yan-ting;YANG Min. Application of the ⁶⁸Ge/⁶⁸Ga Generator in Clinic [J]. Journal of Isotopes, 2017, 30(4): 270-275.
[11]	REN Zheng;LIU Zhan-feng;ZHANG Liang;HOU Jing-hua;WANG Wei;XU Jiang-fei;HOU Jie. Bath Production of High Abundance ¹⁵N Isotope Labeled L-arginine by Microbiological Fermentation [J]. Journal of Isotopes, 2017, 30(2): 131-135.
[12]	CHEN Wen;WEI Hong-yuan;ZHOU Zhi-jun;LUO Shun-zhong. Positron Emission Radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr Labeled PET Drugs [J]. Journal of Isotopes, 2017, 30(1): 78-88.
[13]	HAN Zhen-yi;LIANG Ji-xin;HU Ji;LUO Hong-yi;QING Jing;CHEN Yu-qing;LI Guang;LI Hong-yu. Comparison of Two Kinds of ⁶⁴Cu Labelled Octreotide Analogues [J]. Journal of Isotopes, 2016, 29(2): 82-88.
[14]	WANG Li-zhen;YANG Min. Development of ⁸⁹Zr Labelled Radiopharmaceuticals [J]. Journal of Isotopes, 2016, 29(2): 121-128.
[15]	MA Huan;TANG Yu;YANG Yuan-you;LIU Ning;LIAO Jia-li;YANG Ji-jun. Preliminary Study of Radioiodination of VP2 [J]. Journal of Isotopes, 2016, 29(1): 1-5.

Progress of Preparation and Applications of ⁶⁸Ga-Labelled Radiopharmaceuticals

⁶⁸Ga标记放射性药物的制备及应用研究进展

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics